Status:
TERMINATED
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To define the safety and efficacy of sibling-supplied, HIV antigen-pulsed dendritic cells in increasing the immune response in HIV-infected patients. Dendritic cells are a type of white blood cell us...
Detailed Description
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cel...
Eligibility Criteria
Inclusion Criteria
Patients must have:
- HLA A2+.
- Same cell type as donor sibling.
- CD4 count > 350 cells/mm3.
- HIV asymptomatic status.
- No HIV antivirals during study.
- Normal labs and chest x-ray.
Donor siblings must have:
- HLA A2+.
- HIV negativity.
- Ability to donate cells on multiple occasions.
- Negative status for hepatitis B and C.
Exclusion Criteria
Concurrent Medication:
Excluded:
- Antiviral therapy (unless CD4 count declines to < 350 cells/mm3).
Prior Medication:
Excluded:
- Antiviral therapy within 90 days prior to study entry.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00001064
End Date
June 1 2005
Last Update
December 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Univ School of Medicine
Stanford, California, United States, 943055107